New HIV research from Kenya, presented at the 26th International AIDS Conference, offers crucial insights into tackling drug resistance and treatment failure in Africa.

• The Ndovu study demonstrated that switching to a ritonavir-boosted darunavir (DRV/r)-based regimen showed better viral suppression in patients experiencing dolutegravir (DTG) resistance compared to continuing standard-dose DTG.
• Key researchers from the Center for Epidemiological Modelling and Analysis (CEMA) at the University of Nairobi, including Principal Investigator and CEMA Co-Director Dr. Loice Ombajo, led the presentation of these findings.
• The Sungura Study found that a simpler two-drug HIV treatment regimen is safe for older adults (aged 60 years and above) previously exposed to Hepatitis B, with 98% showing no signs of active infection after 72 weeks.